In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Abiding Myth of Innovation

Executive Summary

The underlying theme of this year's Phoenix meeting was the need to carefully manage through times of rapid change and discontinuity and select appropriate corporate cultures. The medical device industry is, in large measure, built on the notion that small companies deliver the lion's share of innovative technology. But the critical role large companies play in bringing those products to market undermines, to a degree, the power small companies have as innovators. Thus, side by side with the value that innovative or disruptive technology brings is the power of incumbency and entrenched interests. And as the e-health revolution hits the skids, no segment better illustrates the ability of incumbency to take control over the discontinuity that disruptive technology brings than the Internet. There are, in fact, several reasons why even the most innovative devices fall short of being truly disruptive, including the long clinical and regulatory paths they must travel, the aversion most physicians have to products that make them change the way they practice medicine, and the critical role of big companies in marketing.

You may also be interested in...

GSK Tapping Into Naturals Trend With UK Piri Extension

GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.

Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

MeMed Ready To Partner On IVD Technology That Can Cut Antibiotic Overuse

MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts